Emergent BioSolutions Inc/ US29089Q1058 /
2024-03-28 8:59:56 PM | Chg. -0.07 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
2.53USD | -2.69% | 19,685 Turnover: 50,048.56 |
-Bid Size: - | -Ask Size: - | 132.07 mill.USD | - | - |
Assets
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 331.8560 | 376.4480 | 407.2100 | 510.2000 | 542.3000 | ||||||
Intangible Assets | 57.3750 | 33.8650 | 119.5970 | 761.6000 | 712.9000 | ||||||
Long-Term Investments | - | - | - | - | - | ||||||
Fixed Assets | 504.9800 | 459.8930 | 584.8170 | 1,608.6000 | 1,641.1000 | ||||||
Inventories | 76.9360 | 74.0020 | 142.8120 | 205.8000 | 222.5000 | ||||||
Accounts Receivable | 120.7670 | 138.4780 | 143.6530 | 262.5000 | 270.7000 | ||||||
Cash and Cash Equivalents | 312.7950 | 271.5130 | 178.2920 | 112.2000 | 167.8000 | ||||||
Current Assets | 538.6120 | 510.2180 | 485.3890 | 620.8000 | 686.2000 | ||||||
Total Assets | 1,043.5920 | 970.1110 | 1,070.2060 | 2,229.4000 | 2,327.3000 |
Liabilities
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 45.9660 | 34.6490 | 41.7510 | 80.7000 | 94.8000 | ||||||
Long-term debt | 253 | 248.0940 | 13.4570 | 784.5000 | 798.4000 | ||||||
Liabilities to Banks | - | - | - | - | - | ||||||
Provisions | - | - | - | 72 | 63.9000 | ||||||
Liabilities | 383.5750 | 373.9060 | 157.8610 | 1,218.5000 | 1,238.8000 | ||||||
Share Capital | .0400 | - | - | - | - | ||||||
Total Equity | 660.0170 | 596.2050 | 912.3450 | 1,010.9000 | 1,088.5000 | ||||||
Minority Interests | - | - | - | - | - | ||||||
Total liabilities equity | 1,043.5920 | 970.1110 | 1,070.2060 | 2,229.4000 | 2,327.3000 |
Income Statement
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 522.7890 | 488.7820 | 560.8730 | 782.4000 | 1,106 | ||||||
Depreciation (total) | - | - | - | 25 | 58.7000 | ||||||
Operating Result | 96.0390 | 105.5220 | 124.2850 | 89.8000 | 114.1000 | ||||||
Interest Income | -5.9510 | -6.5640 | -4.8370 | -9.9000 | -38.4000 | ||||||
Income Before Taxes | 89.7690 | 99.2210 | 118.6330 | 81.5000 | 77.4000 | ||||||
Income Taxes | 26.8990 | 36.6970 | 36.0390 | 18.8000 | 22.9000 | ||||||
Minority Interests Profit | - | - | - | - | - | ||||||
Net Income | 62.8700 | 51.7760 | 82.5940 | 62.7000 | 54.5000 |
Per Share
Cash Flow
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 44.4590 | 53.4870 | 208.1390 | 41.8000 | 188 | ||||||
Cash Flow from Investing Activities | -45.4620 | -76.2570 | -249.9320 | -897.2000 | -96.9000 | ||||||
Cash Flow from Financing | 33.4490 | -18.6410 | -51.4010 | 788.7000 | -35.9000 | ||||||
Decrease / Increase in Cash | 32.2960 | -41.2820 | -93.2210 | -66.9000 | 55.6000 | ||||||
Employees | 1,292 | 1,098 | 1,256 | 1,705 | 1,834 |